Trophos Increases Focus on Neuroprotection Including Spinal Muscular Atrophy.
December 29, 2008.

Trophos SA, a clinical stage pharmaceutical company based in France developing innovative therapeutics for indications with under-served needs in neurology and cardiology, announced today that the company is increasing the focus of its development programs on neuroprotection and cardioprotection.

TRO19622: development in Spinal Muscular Atrophy (SMA), an orphan neurodegenerative disorder, continues following successful phase Ib study in SMA patients in France. 

The company will continue its development program in SMA with TRO19622 following a phase Ib PK and tolerability study in SMA patients ranging from 6-25 years old in France, which demonstrated good tolerability and established the pharmacokinetic characteristics of the molecule in children. Discussions are ongoing with the EMEA regarding appropriate trial design to demonstrate efficacy and allow registration in this indication.  This program has received financial support from the Association Française contre les Myopathies (AFM).

Read the whole press release here.

Click here for the Trophos web site.